A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia
Abstract We compared the efficacy, safety, and acceptability of lurasidone at different doses to establish the dose–response relationships of lurasidone therapeutic and adverse effects in acute schizophrenia. Included trials were 4- to 16-week, fixed-dose, randomized controlled trials of lurasidone...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-03-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-84836-z |
id |
doaj-8180d6af46654656b599de43a66921d3 |
---|---|
record_format |
Article |
spelling |
doaj-8180d6af46654656b599de43a66921d32021-03-11T12:13:52ZengNature Publishing GroupScientific Reports2045-23222021-03-0111111310.1038/s41598-021-84836-zA network meta-analysis of the dose–response effects of lurasidone on acute schizophreniaManit Srisurapanont0Sirijit Suttajit1Surinporn Likhitsathian2Benchalak Maneeton3Narong Maneeton4Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Si PhumDepartment of Psychiatry, Faculty of Medicine, Chiang Mai University, Si PhumDepartment of Psychiatry, Faculty of Medicine, Chiang Mai University, Si PhumDepartment of Psychiatry, Faculty of Medicine, Chiang Mai University, Si PhumDepartment of Psychiatry, Faculty of Medicine, Chiang Mai University, Si PhumAbstract We compared the efficacy, safety, and acceptability of lurasidone at different doses to establish the dose–response relationships of lurasidone therapeutic and adverse effects in acute schizophrenia. Included trials were 4- to 16-week, fixed-dose, randomized controlled trials of lurasidone in adults with acute schizophrenia. Different doses of lurasidone, other antipsychotics, and placebo were considered as independent treatments. Apart from all-cause dropout rates, four therapeutic and four adverse outcomes were included in the frequentist network meta-analysis (NMA). Lurasidone 160, 120, 80, 40, and 20 mg/day were studied in ten trials of 3,366 adults with schizophrenia exacerbation. Lurasidone 160 mg/day reduced Positive and Negative Syndrome Scale (PANSS) total scores significantly more than lurasidone 120, 80, 40, and 20 mg/day (mean differences = − 7.63, − 7.04, − 8.83, and − 12.25, respectively). All-cause dropout rates were significantly lower in participants receiving lurasidone 160 mg/day and 80 mg/day compared with those taking placebo. The half-maximal effective doses of lurasidone for PANSS total, PANSS positive, and MADRS score reductions were higher than 80 mg/day. The confidence of all NMA estimates was low or very low. Lurasidone 160 mg/day is currently the most efficacious and acceptable dose for acute schizophrenia. Its maximal effective doses may be higher than 160 mg/day.https://doi.org/10.1038/s41598-021-84836-z |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Manit Srisurapanont Sirijit Suttajit Surinporn Likhitsathian Benchalak Maneeton Narong Maneeton |
spellingShingle |
Manit Srisurapanont Sirijit Suttajit Surinporn Likhitsathian Benchalak Maneeton Narong Maneeton A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia Scientific Reports |
author_facet |
Manit Srisurapanont Sirijit Suttajit Surinporn Likhitsathian Benchalak Maneeton Narong Maneeton |
author_sort |
Manit Srisurapanont |
title |
A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia |
title_short |
A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia |
title_full |
A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia |
title_fullStr |
A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia |
title_full_unstemmed |
A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia |
title_sort |
network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia |
publisher |
Nature Publishing Group |
series |
Scientific Reports |
issn |
2045-2322 |
publishDate |
2021-03-01 |
description |
Abstract We compared the efficacy, safety, and acceptability of lurasidone at different doses to establish the dose–response relationships of lurasidone therapeutic and adverse effects in acute schizophrenia. Included trials were 4- to 16-week, fixed-dose, randomized controlled trials of lurasidone in adults with acute schizophrenia. Different doses of lurasidone, other antipsychotics, and placebo were considered as independent treatments. Apart from all-cause dropout rates, four therapeutic and four adverse outcomes were included in the frequentist network meta-analysis (NMA). Lurasidone 160, 120, 80, 40, and 20 mg/day were studied in ten trials of 3,366 adults with schizophrenia exacerbation. Lurasidone 160 mg/day reduced Positive and Negative Syndrome Scale (PANSS) total scores significantly more than lurasidone 120, 80, 40, and 20 mg/day (mean differences = − 7.63, − 7.04, − 8.83, and − 12.25, respectively). All-cause dropout rates were significantly lower in participants receiving lurasidone 160 mg/day and 80 mg/day compared with those taking placebo. The half-maximal effective doses of lurasidone for PANSS total, PANSS positive, and MADRS score reductions were higher than 80 mg/day. The confidence of all NMA estimates was low or very low. Lurasidone 160 mg/day is currently the most efficacious and acceptable dose for acute schizophrenia. Its maximal effective doses may be higher than 160 mg/day. |
url |
https://doi.org/10.1038/s41598-021-84836-z |
work_keys_str_mv |
AT manitsrisurapanont anetworkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT sirijitsuttajit anetworkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT surinpornlikhitsathian anetworkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT benchalakmaneeton anetworkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT narongmaneeton anetworkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT manitsrisurapanont networkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT sirijitsuttajit networkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT surinpornlikhitsathian networkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT benchalakmaneeton networkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia AT narongmaneeton networkmetaanalysisofthedoseresponseeffectsoflurasidoneonacuteschizophrenia |
_version_ |
1724224602643628032 |